Record ID: MS-N071 · Family: Vitamins / radiotherapy interaction / head and neck cancer · Clinical question: Do high-dose alpha-tocopherol and beta-carotene supplements improve tolerance without compromising cancer outcomes?

Evidence label: Randomized evidence found fewer acute toxicities but concerning increases in recurrence/second cancers during supplementation and higher all-cause mortality.

Evidence at a glance

• Benefit: Some acute radiotherapy adverse effects were reduced.
• Certainty: Moderate for this specific high-dose combination because outcomes came from a randomized placebo-controlled trial.
• Risk: Recurrence/second-primary events increased during supplementation, and long-term all-cause mortality was higher.
• Cancer control: The safety signal directly concerns recurrence, second primary cancers and mortality.

What was studied

A double-blind randomized placebo-controlled trial assigned 540 people with stage I or II head-and-neck cancer to alpha-tocopherol 400 IU/day plus beta-carotene 30 mg/day or placebo, beginning on the first day of radiotherapy and planned for three years. Beta-carotene was stopped after 156 participants because of external safety concerns.

Multiple papers report different outcomes from the same trial; they are treated here as one trial, not independent evidence.

What the results show

During supplementation, the hazard of a second primary cancer was higher with antioxidants (HR 2.88, 95% CI 1.56–5.31), as was the combined endpoint of recurrence or second primary cancer (HR 1.86, 95% CI 1.27–2.72). At eight years, the overall proportion remaining free of a second primary cancer was similar between groups, suggesting the excess clustered during exposure.

With median follow-up of 6.5 years and 179 deaths, all-cause mortality was higher in the supplement group (HR 1.38, 95% CI 1.03–1.85). A companion report found a nonsignificant local-recurrence trend (HR 1.37, 95% CI 0.93–2.02) while documenting fewer acute toxicities.

Important limits

• This was one specific high-dose formulation in early-stage head-and-neck cancer; results should not be generalized to food or every antioxidant.
• Stopping beta-carotene early complicates attribution between beta-carotene, vitamin E and their combination.
• Smoking status appeared to modify some effects in secondary analyses.
• Funding and conflict disclosures were reported in the original articles but were not independently re-extracted for this record.

Safety and practical context

High-dose antioxidant vitamins should not be started during radiotherapy without the radiation-oncology team’s agreement. This trial is a reminder that reducing side effects does not prove treatment compatibility; supportive benefit and cancer control can move in different directions.

Questions for the care team

• Is this dose above ordinary dietary intake or a standard multivitamin?
• Does the radiation oncologist recommend avoiding the product during treatment?
• Is there a documented deficiency that requires a different, monitored plan?

Sources checked

• Bairati et al., Journal of the National Cancer Institute 2005 — second primaries and recurrence (PMID 15812073).
• Bairati et al., International Journal of Cancer 2006 — mortality follow-up (PMID 16841333).
• Meyer et al., International Journal of Cancer 2005 — adverse effects and recurrence (PMID 16027437).

Last literature search: October 19, 2026 · Record appraisal: October 19, 2026

Educational information only. This record is not a prescription and does not replace advice from the oncology team or oncology pharmacist.